Reaction-diffusion model as framework for understanding the role of riboflavin in “eye defence” formulations

Francesca Di Nezza, a Ciro Caruso, b Ciro Costagliola a and Luigi Ambrosone a * a

Analysis of UV-visible spectra, performed on commercial riboflavin-based eye drops, showed that absorbance is a saturating function of vitamin concentration. This implies a threshold concentration, C t, such that for riboflavin concentration > C t, the absorbance remains constant and the effectiveness of the eye drops is independent of the dose used. These experimental results were combined with a diffusion–reaction model to elucidate the mechanism of action within the cornea. The model predicts that the eye drops have a low effectiveness on UVB and UVC, while they have a good performance for UVA. Indeed, at the center of the cornea the transmittance is significantly reduced and after 1 h it is reduced by about 70% compared to a cornea devoid of eye drops.

1 Introduction

Ultraviolet (UV) radiation is the part of the electromagnetic spectrum located between X-radiation and visible light. Based on physiological effects it is divided into three primary regions. UV-A 315–400 nm, UV-B 315–280 nm and UV-C 280–100 nm. The ability of UV rays to penetrate biological tissues increases with decreasing wavelength. A prolonged exposure of the eyes to UV radiation may cause acute, or chronic, effects on the cornea, lens and retina. The World Health Organization estimates that about 20% of the 12–15 million people who every year risk blindness is caused by sun exposure. Most of UV radiation incident on the eyes is absorbed by cornea and lens, while only 4% reaches the retina. Awareness of UV radiation damage to the eyes has risen substantially over recent years, this has encouraged pharmaceutical companies to look for formulations protecting stressed ocular tissues. Due their easy use, eye drops are generally the preferred means to apply medications when treating ocular disorders. 3

It is well-known that aqueous solutions of Riboflavin (RBF) (vitamin B2) protects the eye against UV radiation. However, the outermost epithelium, an hydrophobic layer of 50–100 μm, is impermeable to hydrophilic drugs, so that 90% of the instilled dose is lost almost immediately. In order to increase the corneal permeability, compounds such as hyaluronic acid, α-Tocopherol polyethylene glycol 1000 succinate, t-proline, methyl sulfonyl methane and many other additives are added to increase the formulation hydrophobicity. 4 The resulting chemical complexity of the formulation makes difficult to understand the mechanism of action of riboflavin in corneal tissue. Furthermore, RBF is degraded by light and lumichrome is formed by UVA rays or blue light under physiologically neutral conditions. 5 From what has been said about UV protection by RBF it is clear that the elucidation of the basic mechanism can be attained only by studying how the molecular diffusion and RBF oxidation are related to cornea structure and how, in turn, the protection process is related to the physicochemical properties of eye drops. The goal of this study is to clarify how to use experimental results from UV-visible absorption spectra to predict the behavior of the eye, treated with RBF-based eye drops, when it is exposed to UV radiation. We find that UV-spectra provide useful data to be processed in a diffusion–reaction model to predict the amount of RBF present in the cornea and thus to trace tissue-transmittance characteristics. The mathematical complexity inherent in a diffusion–reaction model is overcomes with isolating two regimes of reaction which to a great extent are independent which lead to simple phenomenological equations. 6 In this paper absorption spectra of a commercial eye drop are used to elaborate a diffusion–reaction model to evaluate the degree of UVA UVB absorption RBF. Although the model is applied to corneal tissue, it is mathematically presented in a dimensionless form to be extended to other types of RBF administrations a diffusion–reaction model to evaluate the efficacy of RBF in commercial eye drops is discussed. The model is presented in dimensionless form to be applied for different administrations, although in the paper it is applied for the protection of the corneal tissue.

2 Theoretical aspects

2.1 Diffusion model

When a drop of drug-solution is posed on biological tissue, as in the in vivo case, it becomes wetted, triggering a liquid–solid
mass transfer process, providing a means for the drug diffusion in the tissue.

At time \( t = 0 \) a volume \( V \) (typically 0.05 cm\(^3\)) of Drop Defence containing \( N \) molecules of RBF is placed on the cornea, so that a \( C_0 \) concentration of vitamin B\(_3\) is present on its outer surface. Such solution is assumed to be uniform, namely there are no concentration gradients, and it remains constant until the next instillation. A rate balance over an element in the cornea gives

\[
\frac{\partial C}{\partial t} = D \nabla^2 C + r(C)
\]

where \( D \) is the diffusion coefficient of RBF in the cornea, \( t \) is the time, \( \nabla^2 \) is the Laplacian operator. The reaction term, \( r(C) \) is an empirical expression. In general, the Laplacian operator involves all three spatial coordinates, but we will be concerned mainly with systems where the symmetry allows this diffusion term to be written as a function of a single spatial coordinate. Furthermore, it is experimentally ascertained that UV radiation causes damage even to the retina, that is to say at a distance much greater than the corneal thickness. Therefore, we model the system as an infinite cylinder in which the diffusion in the radial direction may be neglected. Interestingly if oxygen is present in the tissue the oxidative degradation of RBF may take place. The rate of photolysis of RBF molecules depends on state of ionization of the molecule and its susceptibility to excitation and subsequent degradation on exposure to light. This reaction, studied under different experimental conditions, was found to be a pseudo first order kinetics.

Thus concentration at position \( x \) and time \( t \) assumes the form

\[
\frac{\partial C}{\partial t} = D \frac{\partial^2 C}{\partial x^2} - KC
\]

subject to the conditions

\[
\begin{align*}
C(x, 0) &= 0 \\
C(0, t) &= C_0 \\
\lim_{x \to \infty} \frac{\partial C}{\partial x} &= 0
\end{align*}
\]

which ensure a \( C_0 \) concentration of RBF at the outer corneal surface. Both the diffusion coefficient and the first pseudo order constant are assumed to be independent of concentration. By applying the Laplace transform method one can calculate the following solution

\[
C(x, t) = \frac{C_0}{2} \left[ e^{-\sqrt{\frac{D}{t}}} \text{erfc}\left(\frac{x}{\sqrt{4Dt}} - \sqrt{Kt}\right) + e^{\sqrt{\frac{D}{t}}} \text{erfc}\left(\frac{x}{\sqrt{4Dt}} + \sqrt{Kt}\right)\right]
\]

Depending on the relative rates of diffusion and chemical reaction one of them would control the overall kinetics. Specifically diffusion will control if reaction rate is fast. To delineate these regions, we introduce a diffusion lifetime, \( t_0 = \frac{a^2}{D} \), and a reaction lifetime, \( t_R = \frac{1}{K} \), where \( a \) is a characteristic system length. Then we convert eqn (4) to non-dimensional form adopting as unit of length \( \ell \) and time \( \ell_0 = \ell^2/D \). In these units, with appropriately scaled quantities

\[
X = x/\ell \quad \text{and} \quad \tau = t/\ell_0 = t \ell^2/D
\]

concentration profile as an equation containing only one control parameter, is obtained

\[
C(\ell, \tau) = \frac{C_0}{2} \left[ e^\frac{\tau}{2} \text{erfc}\left(\frac{\ell}{\sqrt{4\ell_0\tau}} - \sqrt{\frac{2K}{\ell^2}}\right) + e^{-\frac{\tau}{2}} \text{erfc}\left(\frac{\ell}{\sqrt{4\ell_0\tau}} + \sqrt{\frac{2K}{\ell^2}}\right)\right]
\]

### 2.2 Electromagnetic-radiation absorption

An electromagnetic wave incident on a material undergoes an attenuation and its intensity is reduced by absorption. This latter phenomenon is physically described by absorption coefficient, \( \sigma \), defined as the ratio between the intensity absorbed in the unit volume and the intensity incident per unit area. With reference to a light beam propagating along \( x \) direction, the fraction of intensity lost \( \frac{dI}{I} \) in the volume element, \( dV \), is

\[
\frac{dI}{I} = \sigma dV \quad \text{or} \quad \frac{dI}{I} = \sigma dx
\]

where \( \Sigma \) is the cross section of the beam, \( I \) is the impinging intensity and \( dV = \Sigma dx \).

Integrating eqn (7), Lambert–Beer law is obtained

\[
\frac{I}{I_0} = \exp\left(-\int_0^x \sigma \, dx\right)
\]

The variation of intensity passing through the volume element, therefore, is in eqn (8) the coefficient \( \sigma \) takes into account the overall attenuation suffered by the radiation, in the considered volume. However, if the system is composed of two or more phases, each individual contributes has to be explained. In our model, phases consist of a liquid solution (eye drops) and a solid medium (cornea) so that absorption coefficient can be rewritten as

\[
\sigma = \sigma^l(\lambda, C) + \sigma^s(\lambda)
\]

where \( \sigma^l \) and \( \sigma^s \) are liquid and solid absorption contributes, respectively. The solid term depends only the wavelength of the radiation passing through the material and it represents the inverse of the penetration depth, \( \delta_p \) of that specific radiation in the material:

\[
\sigma^s(\lambda) = \frac{1}{\delta_p(\lambda)}
\]
terms of parameters with clear physical significance, in order that system properties may be related to experimental results. Thus, we write

$$\sigma(\lambda, C) = \vartheta(\lambda, C)C$$  \hspace{1cm} (11)

where the function $\vartheta(\lambda, C)$ reflects the nonideality of the system. To relate the function $\vartheta(\lambda, C)$ to the experimental quantities, one must bear in mind that the molar extinction coefficient, $\varepsilon(\lambda, C)$ is defined in terms of decimal logarithm, therefore

$$\vartheta(\lambda, C) = \ln_{10} \varepsilon(\lambda, C)$$ \hspace{1cm} (12)

Finally, substitution of eqn (11), (12) and (9) into (8) results in

$$I(X, T) = e^{-\int_{0}^{X} \mathcal{A}_{}^{\text{exp}}(\lambda, C(X', T)) \, dX'}$$ \hspace{1cm} (13)

where

$$\mathcal{A}^{\text{exp}}(\lambda, C) = \varepsilon(\lambda, C)Cl, \quad \Delta_p = \frac{\delta_d}{\gamma^2}$$ \hspace{1cm} (14)

are the spectrophotometrically measured absorbance, $\Delta_p(\lambda)$ the dimensionless penetration length. In addition, the parameter $s$ takes into account that in a spectrophotometric measurement the length is measured in cm, while in the diffusion process it is arbitrary. Eqn (13) establishes that the transmittance of the UV radiation in the cornea can be calculated if RBF concentration profile, cross the ocular tissue, is known.

3 Materials and methods

3.1 Chemicals

Ophthalmic antioxidant formulation, termed drop defence, was kindly offered by Iros sc. r.l. (Italy), patent no. EP 2459186, USP 9192394). According to the manufacturer drop defence is a mixture of riboflavin (RBF), $\alpha$-tocopheryl polyethylene glycol (TPGS vitamin E), proline, glycine, lysine and leucine solution, pH 7.2-7.4. Phosphate buffered saline (PBS) solution was prepared dissolving one tablet, purchased by Sigma Aldrich, into 0.2 dm$^3$.

3.2 Solutions preparation

Since the detailed composition of the eye drops is patented, the concentration of the individual constituents was varied by diluting the commercial sample by means of PBS buffer solutions (10 mM, pH 7.2). In order to reduce volume errors due to dilution, all solutions were always prepared by dilution of the eye drops and not by subsequent dilutions. This means that if $C_0$ is the initial concentration of any solution constituent, after dilution the concentration turns out to be

$$\alpha = \frac{C}{C_0}$$ \hspace{1cm} (15)

$\alpha$ being the dilution factor.

As regard vitamin B$_2$ the initial concentration was found to be $C_0 = 1.3$ mM.

3.3 Methods

3.3.1 Spectrophotometry. The absorption measurements were carried out with a Cary 100-Variante UV-Vis equipped with thermostatted cuvettes. Samples were placed in a rectangular quartz cuvettes of 1 cm path length and absorption spectra were recorded at $(25 \pm 0.5) ^\circ$C in the 200–800 nm wavelength region.

4 Results and discussion

4.1 Absorption spectra

Fig. 1 shows absorption spectra of a commercial eye defence measured at $25 ^\circ$C as a function of the dilution factor $C/C_0$. As one can see, each spectrum is characterized by one peak in visible light range at 445 nm and three peaks in UV range at 220, 266, 373 nm, respectively. Absorption of light in the UV-visible region is due to electronic transitions between ground state and excited state valence electrons. The complex shape of RBF spectra displayed in Fig. 1 is due to the superposition of rotational and vibrational transitions with electronic transitions, which gives a jumble of overlapping lines appearing as a continuous absorption band.$^{14}$ Comparing the wavelengths of experimental peaks with the physiological ranges of UV radiation, one realizes that $\lambda = 371$ nm falls in the UVA range while other two peaks lie in the UVC range. Therefore, the effect of RBF concentration was studied by monitoring, as a function of $C/C_0$, absorbance peaks at 370 and 260 nm as well as at 300 nm. Results are displayed in Fig. 2. An detailed numerical analysis indicates that experimental results are well-described by a saturation curve of the type:

$$\mathcal{A}^{\text{exp}} = \mathcal{A}^{\text{max}} \frac{m_1 \alpha}{1 + m_2 \alpha}$$ \hspace{1cm} (16)

where $\mathcal{A}^{\text{max}}$ and $m_1$ two adjustable parameters and $\alpha$ is given by eqn (15).

Fig. 1. Experimental absorption spectra of commercial eye defence as a function of the dilution factor. In the column, on the right, the sample concentration expressed as a fraction of the initial concentration $C_0 = 1.3$ mM is indicated.
Finally for making the electrons less available to pass in excited states.

ribo...

follows that threshold concentration depends on substance. If, then, RBF undergoes oxidative degradation with a large excess of RBF implies a large amount of unused (nm) molecules in eye defence, at 370, 267, 300 nm; second row (from left to right): reciprocal of $\alpha_{\text{exp}}$ vs. reciprocal of $\alpha$ for $\lambda$ = 370, 267 and 300 nm.

The curve shape was further studied by plotting reciprocal of $\alpha_{\text{exp}}$ vs. reciprocal of $\alpha$, as shown in Fig. 2. As one can see, for all cases investigated, experimental data-points exhibit an excellent linearity. Hence, we are very confident that eqn (16) is a good representation of the experimental data. Curve-parameters computed by means of best-fitting to experimental data-points are collected in Table 1. It is noteworthy that $\alpha_{\text{max}} = 1$ is independent of $\lambda$, while $m_2$ is strongly dependent on the wavelength. Accordingly, experimental curves are substantially described by a single parameter, for any RBF concentration.

Introducing eqn (15) into (16), $\alpha_{\text{exp}}$ is rewritten as

$$\alpha_{\text{exp}} = \alpha_{\text{max}} \frac{C}{C_1 + C}$$

(17)

where

$$C_1 = C_0/m_2$$

(18)

In this form it is immediately seen that there exist a threshold concentration which determines two regimes. For $C < C_1$, $\alpha_{\text{exp}}$ increases linearly with slope $\alpha_{\text{max}}/C_1$, while for $C > C_1$ it remains practically constant. Likely, at high concentrations, riboflavin molecules associate in dimers, trimers, $n$-mers forms, making the electrons less available to pass in excited states. Finally for $C = C_0$, $\alpha_{\text{exp}} = \alpha_{\text{max}}/2$. From the definition of $C_0$, it follows that threshold concentration depends on $\lambda$ and $C_0$. At first glance, therefore, one might be tempted to conclude that, at high $C_0$, the eye drops should give an excellent UV absorption. A second look, however, shows that this conclusion is not justified because from $C_0$ onwards the absorbance is constant, a large excess of RBF implies a large amount of unused substance. If, then, RBF undergoes oxidative degradation with formation of free radicals, one realizes that RBF quantity to be used must be calibrated in order that have small $C_1$ and low probability of the oxidation reaction.

In this regard, it can be seen from Fig. 1 that absorption spectra exhibit two minima around $\lambda = 420$ and 320 nm, which correspond to a greater transmittance. Since sunshine has a high emission at 420 nm, one could deduce that eye defence formulation is not very protective. However, it is equally evident from Fig. 1 how the spectrum is dependent on the riboflavin concentration, i.e. it is dose-dependent. This means that a suitable dosage of the formulation minimizes the transmittance effect at 420 nm. Particularly, for RBF concentration $C = 0.5$ g L$^{-1}$ the absorption minima disappear almost completely. Furthermore, even if, at these wavelengths, the refractive index between the formulation and the eye surface were such as to reduce reflection the transmitted light would be negligibly low.

In concluding this section, we should note that the energy stored in the absorption process may be released by emitting a longer wavelength radiation. In short, absorbent molecules behave like fluorophores and the material is seen to be fluorescent. With regard to eye defence formulation, preliminary measurements on material samples have shown that an excitation at 450 nm produces a high intensity of fluorescence emission at 526 nm, strongly dependent on RBF concentration. Obviously, such emission represents a new source of radiation. Fortunately, 526 nm wavelength corresponds to the green color, which is not harmful to the eye, indeed may use to visualize some corneal lesions. That is to say, a eye treated with this formulation, when irradiated with white light, the green light emitted by fluorescence reveals a corneal lesions. Clinical research has been initiated on this point.

### 4.2 Numerical results

It is easy to convince oneself that whenever diffusion of RBF molecules occurs in cornea, it has a marked effect on the UV-transmittance of ocular tissue. It, perhaps, not quite so obvious that oxidative effects, when they occur are of major importance. The reason for this is that the extent of degradation is a strong function of the RBF concentration. Thus, the combined action of these two effects determines the UV-exposure response of the cornea treated with RBF-based eye drops. To model both actions we only have to introduce eqn (6) and (17) into (13) and to solve the integral. In order to apply the model numerically it is necessary to know the external parameters.

McQuaid et al.$^{15}$ analyzed the penetration rate of RBF molecules through the stroma. Their measurements provide a diffusion coefficient $D = 6.5 \times 10^{-7}$ cm$^2$ s$^{-1}$. In a kinetic study of RBF photolysis in aqueous solution by UV-visible radiation, the apparent first-order rate constant, $k$, at different pH values was measured.$^{16}$ Such experimental results were used to interpolate $t_k = 1/k = 0.91 \times 10^7$ s. By means of these experimental data the control parameter at $p = 0.23$ was determine, then the concentration profile as function of $X$, $t$ can be calculated. Nevertheless, in order to evaluate the total transmittance it is

| $\lambda$ (nm) | $\alpha_{\text{max}}$ | $m_2$ |
|---------------|---------------------|------|
| 370           | 1.0 ± 0.2           | 58 ± 6 |
| 300           | 1.3 ± 0.5           | 2.9 ± 0.2 |
| 267           | 1.1 ± 0.1           | 21 ± 3 |
necessary to know the penetration length of UV rays in cornea.\textsuperscript{17} From data by Kolozsvári \textit{et al.}\textsuperscript{17} was computed $\delta_p = 0.19$ cm, for $\lambda = 373$ nm; $\delta_p = 0.0090$ cm, for $\lambda = 300$ nm; and $\delta_p = 0.0269$ cm, for $\lambda = 266$ nm. Finally, making use of results in Table 1, the transmittance was numerically calculated as a function which maps a pair of values $(X, \bar{t})$ inside the cornea to the UVA-transmission. Results, visualized in Fig. 3 as three-dimensional plots, indicate that UVB radiation is rapidly attenuated and completely absorbed within $X = 0.4$, \textit{i.e.} 40\% of cornea length. UVC radiation is less rapidly attenuated, but anyhow it is absorbed within $X = 0.90$, that is to say 90\% of cornea length. At investigated wavelengths, $\Delta p$ is very small so that the pre-integral term in eqn (13) causes a very strong damping, regardless of the integral value. In other words, the chemical composition of the cornea protects it against UVB and UVC radiation. Accordingly, RBF-based eye drops have a negligibly small effectiveness in this UV range. In Fig. 3 one can see that UVA attenuation occurs along the whole cornea and absorption is significantly dependent on the RBF concentration. Such an analysis is general and may always be applied to determine the absorptive properties of the system under investigation. However, it is not practical to do so because the necessary integrations require that an analysis of 3D-plots be available. A more useful and alternative equation is needed for predictive calculation of absorbance in the cornea. Such an equation is obtained by taking into account that $C_i$ identifies two regimes with different absorptive characteristic.

### 4.2.1 Low concentrations.

In this concentration regime $C(X, \bar{t}) < C_i$ and eqn (17) is simplified into

$$ \alpha_{\exp} = \alpha_{\max} \frac{C(X, \bar{t})}{C_i} $$

(19)

accordingly eqn (16) is analytically solved and results in

$$ \frac{I(Y, \bar{t})}{I_0} = e^{-\frac{X}{e^{G(X, \bar{t})}}} $$

(20)

where

$$ q = \int_{p_0}^{p_{\max}} p_{\max} \, dp $$

(21)

and

$$ G(X, \bar{t}) = \frac{e^{py} \text{erfc}\left(\frac{y}{\sqrt{4t}} + pv\bar{t}\right) - e^{py} \text{erfc}\left(\frac{y}{\sqrt{4t}} - pv\bar{t}\right)}{2} + \text{erf}\left(pv\bar{t}\right) $$

(22)

![Fig. 3 3D-plot of transmittance as a function of $(X, \bar{t})$.](image)

In eqn (20) the first exponential is the cornea contribution to UVA attenuation, the second one is the effect of eye drops. This latter depends both on the molecular properties of RBF and on its spatio-temporal evolution. Such contribution was studied by analyzing separately both the dependence on $X$ and on $\bar{t}$. In order to evaluate behavior as a function of time, we first divide $X$-axis in the region $[0, 1]$ into intervals of size $0.1$. Then $X_n = n/10$ defines points which span the $X$-axis contained within the cornea. The next step consists of applying eqn (20) for each fixed $X_n$. Results collected in Fig. 4 shown that, for each $n$, $I/I_0$ decreases until it reaches a plateau, where the attenuation is saturated. For $t_{1/2} = \frac{p_{\max}}{p} \ll 1$ photo-dissociation reaction is slow compared with diffusion, implying that molar density of RBF inside the cornea is governed by on molecular diffusion. For example, with aid of Fig. 4, one finds that for $n = 1$ the attenuation saturates in 7 min, while for $n = 0.5$ after 30 min.

In order to calculate the transmittance as a function of $X$, the time $\bar{t}$ is probed at intervals of 0.1. Results displayed into Fig. 5 indicate that the transmittance saturates to large distances $X$. For long times all curves converge in a limit curve (blue curve in Fig. 5). This empirical result can also be analytically predicted by verifying that

$$ \lim_{\bar{t} \to \infty} G(X, \bar{t}) = 1 - e^{-\frac{X}{y}} $$

(23)

In Fig. 5, the attenuation of the cornea without eye drops is also plotted for comparison (red curve). Careful analysis of the plot makes it clear that eye drops significantly reduce transmittance. Indeed, at the center of the cornea, in the absence of eye drops, $I/I_0 = 0.85$, while in the presence, after 1.2 h the transmittance becomes 0.21, with a net gain of 75\%.

### 4.2.2 High concentrations.

The region of high concentrations identified by $C(X, \bar{t}) > C_i$ so that by virtue of eqn (6) $\alpha_{\exp} = \alpha_{\max}$ and the transmittance becomes

$$ \frac{I}{I_0} = e^{-\left(\frac{X}{\sqrt{e^{G(X, \bar{t})}}}ight)} $$

(24)
It is clear that UVA intensity decreases exponentially regardless of time and RBF concentration. It could be said that the eye drops behaves like a liquid with an attenuation coefficient of $s\Delta u_{\text{max}}$. As it was experimentally found to be $\Delta u_{\text{max}} = 1$ (see Table 1) the pseudo penetration length, $s$, is well-determined by $m_1$ and $p$. The UVA radiation attenuation is determined both by the chemical structure of RBF and by its kinetic and reactive properties. Interestingly, in this concentration range $s\Delta u_{\text{max}} = 50$, i.e. the contribution of attenuation must be attributed almost exclusively to eye drops.

4.2.3 Transition point. This point is identified by the relationship $C(X, t) = C_t$. As one can derive from eqn (17), such relationship represents the condition for which within the cornea $\Delta u_{\text{exp}} = 1/2$. Hence the transmittance becomes time independent, i.e. a steady-state is triggered. Eqn (7) and experimental results of Table 1 allow us to obtain $C_t = 0.065 \text{ mM}$. Solutions of the equation $C(X, t) = 0.065$ determine a curve representing the contour line connecting those points where RBF concentration 0.065 mM. Numerical results are plotted in Fig. 6. As it can be seen, along the cornea, the limit value is reached at longer times. An equality of the form $C(X, t) = C_t\Delta u_{\text{exp}}$ is satisfactory. Fig. 6 shows that the limit concentration along the cornea is reached at different times, as a result of the molecular diffusion. From plot it is easily deduced that the end of the cornea experiences the limit value after 1.2 hours. In other words, in an eye drops-loaded the steady-regime is reached in 1 hour. Interestingly, the actual attenuation coefficient is $s/2$ and the corresponding transmittance becomes from this plot it is easily deduced that the end of the cornea experiences the limit value after 1.2 hours. In other words, in an eye drops-loaded the steady-regime is reached in 1 hour. Interestingly, in this point the eye drops-attention is $q/2$ so that the steady-attention region can be uniquely outlined:

$$e^{-\left(\frac{t}{t_{\text{ff}}}\right)^2} \leq \frac{I(X)}{I_0} \leq e^{-\left(\frac{t}{t_{\text{ff}}}\right)^2}$$

(25)

5 Conclusions

When UV radiation strikes a corneal surface, some will be reflected in the air interface without entering the cornea. As radiation is propagated within the interior of cornea, it is attenuated by absorption of the corneal tissue. Thus the presence of RBF-based eye drops will decrease penetration of UVA radiation. Mainly because of the presence of the UV-screening pigments, the gradients of UV radiation are steeper than those for visible radiation. The leaf epidermis is the first layer to be directly exposed to solar UV radiation. The penetration of UVR radiation within cornea is largely attenuated by the epidermal layer. UVA, UVB and UVC exert different effects on biological tissue, determined by their respective wavelengths. RBF-based eye drops are generally used to protect the eyes from UV radiation. Diffusion of RBF into cornea plays an important role in the eyes-protection both against UVA-radiation and oxidation process of the ocular tissue due to air-oxygen or a specific diet. In order to understand the mechanism of cornea protection exerted by vitamin B2 not only measurements of molecular absorption are sufficient, but it is necessary to develop an appropriate mathematical model to evaluate the level of attenuation of UV radiation in the ocular tissue. The diffusion–reaction approach herein developed combines experimental results with molecular diffusion model. Indeed, spectrophotometric measurements reveal that the commercial eye drops is ineffective for UVB and UVC. On the contrary, it is efficient for UVA protection.
A detailed numerical investigation of the experimental data shows that the attenuation as a function of RBF concentration is a saturation curve. This implies that there exist a threshold concentration, $C_0$, that identify two operating regimes. For $C > C_0$, the system reaches the steady-state, which is reached at different times along the entire cornea. In practical terms this point is very important as it allows to predict the behavior of the eye drops and what will be its maximum protection against UVA rays.

One of the requirements for a successful model in physical-chemistry science is judicious simplification. If one wishes to do justice to all aspects of the problem, one very soon find oneself in a hopelessly complicated situation and thus, in order to make progress, it is necessary to ignore certain aspects of a chemical situation and to retain others; the wise execution of the choice often makes the difference between a result which is realistic and one which is merely academic. The semiempirical model herein discussed, is an attempt to choose simplifying assumptions which make the problem tractable and yet do not greatly violate chemical-physical reality. Indeed, from the kinetic results of photodegradation of RBF in aqueous solution, which takes place with the formation of free radicals, we estimate the half-life $t = 18$ h. In addition, the eye defence formulation contains sodium hyaluronate and vitamin E, which act as electron scavengers, therefore the residence time of RBF molecules in the reaction environment is even longer. Anyhow, such a time is certainly longer than the actual time of operating of the formulation, as experienced on patients. For any substance, regardless of mechanism, all kinetic properties of interest can be calculated from lifetime measurements. Finally, model tries to describe, in terms of basic concepts of physical chemistry, some results experienced in the ophthalmological field. We assume the diffusion as a driving force of RBF molecules through the cornea and their average residence time in the biological tissue is used to model side reactions, which can reduce the absorbent effect of the chromophores.

**Conflicts of interest**

There are no conflicts to declare.

**Acknowledgements**

We are grateful the Iros sc S.r.l. (Italy) for providing us with the eye drops Drop Defence used in this study.

**Notes and references**

1. C. Caruso, R. L. Epstein, C. Ostacolo, L. Pacente, S. Troisi and G. Barbaro, *Cornea*, 2017, 36, 600–604.
2. C. Ostacolo, C. Caruso, D. Tronino, S. Troisi, S. Laneri, L. Pacente, A. D. Prete and A. Sacchi, *Int. J. Pharm.*, 2013, 440, 148–153.
3. S. Chaudhuri, S. Batabyal, N. Polley and S. Pal, *J. Phys. Chem. A*, 2014, 118, 3934–3943.
4. A. Budroni, C. Thomas and A. De Wit, *Phys. Chem. Chem. Phys.*, 2017, 19, 7936–7949.
5. L. Ambrosone, *Phys. B*, 2000, 292, 136–152.
6. C. Caruso, G. Barbaro, R. L. Epstein, D. Tronino, C. Ostacolo, A. Sacchi, L. Piacente, A. D. Prete, M. L. Sala and S. Troisi, *Cornea*, 2016, 35, 659–662.
7. J. Francis and D. Dickton, *J. Nutr. Health Food Eng.*, 2015, 2, 221–223.
8. M. A. Sheraz, S. H. Kazi, S. Ahmed, Z. Anwar and I. Ahmad, *Beilstein J. Org. Chem.*, 2014, 10, 1999–2012.
9. L. Ambrosone, V. Vitagliano, C. D. Volpe and R. Sartorio, *J. Solut. Chem.*, 1991, 20, 17199–17207.
10. S. Alterovitz and M. Gershenson, *J. Comput. Phys.*, 1975, 19, 121–133.
11. F. Venditti, G. Bufalo, F. Lopez and L. Ambrosone, *Chem. Eng. Sci.*, 2011, 66, 5922–5929.
12. C. Yang, J. Qiu and J. Wang, *Abstr. Appl. Anal.*, 2014, 36, 1–8.
13. R. B. White and F. F. Chen, *Plasma Phys.*, 1974, 16, 565–587.
14. A. Puglisi, T. Giovannini, L. Antonov and C. Cappelli, *Phys. Chem. Chem. Phys.*, 2019, 21, 15504–15514.
15. R. McQuaid, M. Mrochen and B. Vohnsen, *J. Cataract Refract. Surg.*, 2016, 42, 462–468.
16. I. Ahmad, Q. Fasihullah, A. Noor, I. A. Ansari and Q. M. Ali, *Int. J. Pharm.*, 2004, 280, 199–208.
17. L. Kolozsvalár, A. Nőgrádi, B. Hopp and Z. Bor, *Investig. Ophthalmol. Vis. Sci.*, 2002, 43, 2165–2168.
18. M. Mosca, L. Ambrosone, F. Semeraro, D. Casamassima, F. Vizzarri and C. Costagliola, *Int. J. Food Nutr. Sci.*, 2014, 65, 235–240.
19. C. Ke, L. Sun, D. Qiao, D. Wang and X. Zeng, *Food Chem. Toxicol.*, 2011, 49, 2670–2675.
20. H.-Y. Zhang and H.-F. Ji, *New J. Chem.*, 2006, 30, 503–504.